RAZELLE KURZROCK, MD, is a world-renowned leader in precision medicine and immunotherapy. As a board-certified medical oncologist, practicing physician, and researcher, she is recognized as one of the 25 most important voices in precision medicine worldwide and one of the most highly cited scientists globally. She recently joined the Medical College of Wisconsin Cancer Center as Associate Director of Clinical Research and of Precision Science, and the Linda T and John A Mellowes Endowed Chair of Preicison Oncology, overseeing the development of a new Precision Oncology and Rare Cancers initiative and assuming leadership of the adult cancer clinical trial enterprise.
Dr. Kurzrock is best known for founding and chairing the largest Phase 1 clinical trials department in the world while at the University of Texas MD Anderson Cancer Center. The program's focus on precision medicine strategy solidified her standing as a pioneer in the development of personalized medicine.
More recently, at the University of California, San Diego Moores Cancer Center, Dr. Kurzrock established the Rare Tumor Clinic and assumed leadership of both the Center for Personalized Cancer Therapy and Experimental Therapeutics Program.
Today, she serves as Chief Medical Officer for the WIN Consortium for Personalized Cancer Therapy, a non-profit organization committed to bringing personalized cancer medicine to patients around the world. She is also Chief Medical Advisor and co-founder of CureMatch, Inc., a leader in artificial intelligence-based precision medicine, and serves on the Board of both CureMatch and CureMetrix.
Dr. Kurzrock's efforts focus on genomically-driven therapy and precision immunotherapy, especially for treatment of rare cancers. She is currently the Principal Investigator for the TRACK study (Target Rare Cancer Knowledge), sponsored by the TargetCancer Foundation. The study brings together an expert panel of cancer clinicians and scientists to advance knowledge of overlooked rare cancers.
Dr. Kurzrock has served as principal investigator on more than 100 clinical trials and brought oversight to more than 500 trials, resulting in FDA approvals for multiple new cancer therapies. She is the author of more than 850 peer-reviewed articles in a variety of elite medical journals and holds a highly exceptional Hirsch index (h-index) score of 130, with over 75,000 citations.
Her strong record of competitive funding is comprised of approximately $125 million in lifetime funding, which includes nearly $50 million in research support from the National Institutes of Health.
Dr. Kurzrock received her medical degree from the University of Toronto, Canada. She is passionate about sharing her extensive cancer research knowledge. She continues to offer her consultation to several biopharmaceutical companies and is an active voice on national and international stages.
MARCIA K. HORN, JD is the president and CEO of ICAN, International Cancer Advocacy Network.
At ICAN, Marcia is a research advocate who has directly navigated many thousands of complex cancer patient cases pan-tumor since the founding of the organization in 1996. She is also a molecular profiling advocate, a clinical trials matching advocate, an expanded access program advocate, a public policy advocate, and a health equity advocate.
Since March 2017, Marcia has also served as the Executive Director of the Exon 20 Group (https://exon20group.org), an international multi-stakeholder coalition created to transform cancers caused by rare and lethal insertion mutations into manageable and survivable conditions. The Exon 20 Group provides more than 25 services to patients, care partners, and additional stakeholders and launched an International Research Consortium and developed plans for a Knowledge Bank project.
Marcia is one of the two research advocates selected for both the Stand Up 2 Cancer Molecular Early Detection of Colon Cancer Dream Team and the Stand Up 2 Cancer InTIME Dream Team for Lung Cancer Interception. She served for three years as DIA's inaugural chairman of its Patient Engagement Community and is a PCORI Ambassador.
Marcia is in her seventh year as a member of the ASCO TAPUR Study Molecular Tumor Board, and has served nearly eight years on the Banner MD Anderson (Gilbert, Arizona) Oncology Panel/ Banner Health Institutional Review Board. She is the advocate for the SWOG Early Therapeutics/Rare Cancers Committee which is chaired by Razelle Kurzrock, MD.
She is a research advocate for the National Cancer Institute's University of Texas Southwestern Medical Center/MD Anderson Cancer Center Lung Cancer SPORE (Specialized Program of Research Excellence).
Marcia graduated Phi Beta Kappa from Stanford University in Political Science and received her JD from Stanford Law School. Before joining ICAN, she practiced litigation and appellate law in Phoenix and had major leadership roles in the arts and civic organizations in Arizona.